Renaissance Technologies LLC Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Renaissance Technologies LLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 26.4% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,685,122 shares of the specialty pharmaceutical company’s stock after buying an additional 351,900 shares during the quarter. Renaissance Technologies LLC’s holdings in Supernus Pharmaceuticals were worth $45,077,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Supernus Pharmaceuticals by 4.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 555,930 shares of the specialty pharmaceutical company’s stock valued at $16,089,000 after acquiring an additional 24,684 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Supernus Pharmaceuticals by 35.9% in the 4th quarter. BNP Paribas Financial Markets now owns 53,432 shares of the specialty pharmaceutical company’s stock worth $1,546,000 after purchasing an additional 14,129 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Supernus Pharmaceuticals by 6.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,456,369 shares of the specialty pharmaceutical company’s stock worth $71,089,000 after purchasing an additional 141,586 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in Supernus Pharmaceuticals by 1,117.6% in the 4th quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 1,330 shares during the period. Finally, Norges Bank purchased a new stake in Supernus Pharmaceuticals during the 4th quarter valued at approximately $7,963,000.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $31.72 on Wednesday. The stock has a market capitalization of $1.74 billion, a PE ratio of -109.45 and a beta of 0.88. Supernus Pharmaceuticals, Inc. has a 1-year low of $21.99 and a 1-year high of $35.44. The business has a 50 day simple moving average of $31.80 and a two-hundred day simple moving average of $30.42.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The business had revenue of $168.30 million for the quarter, compared to analysts’ expectations of $148.83 million. During the same period in the previous year, the company earned ($0.02) EPS. Supernus Pharmaceuticals’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current fiscal year.

Analysts Set New Price Targets

SUPN has been the subject of a number of research reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Piper Sandler downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $41.00 to $36.00 in a report on Wednesday, September 11th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.